Some avenues to cancer diagnosis in the UK seem to be improving, with new data from Public Health England showing a shift in the way new cases are detected.
News
Biosimilar Avastin wins EU approval
European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region.
Biogen ‘optimistic’ for NHS access to Spinraza
Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales.
Sanofi shells out $11.6bn on Bioverativ
Sanofi is fortifying its presence in the field of blood disorders through the purchase of Bioverativ in a deal valued at some $11.6 billion.
Cancer blood tests detects 8 tumour types
Detects 5 kinds of cancer with no current screening tests for average-risk individuals
NHS struggles to fund sustainability projects: report
Money has instead been spent on coping with existing pressures, says National Audit Office report
Sandoz and Biocon to jointly develop ‘multiple’ biosimilars
Novartis’ Sandoz has formed a global partnership with Biocon to develop, manufacture and commercialise multiple biosimilars in immunology and oncology.
International Clinical Researcher of the Year – Still time to enter
There is still time to fill out the MCQ and submit your essay for the prestigious PharmaTimes International Clinical Researcher of theYear competition – but with less than two weeks to go until entries close, you should start the process now.
Report calls for urgent action on R&D model
“Urgent action” is required to boost the productivity of the UK’s R&D model, which is grappling with “unprecedented pressure”, claims a new report by Medicines Discovery Catapult and the BioIndustry Association.
GPs dealing with ‘unsafe’ work load
GPs in the UK are dealing with an average of 41.5 patient contacts every day, which is 60 percent more than what is deemed safe by peers in Europe, an investigation by Pulse has revealed.
Research backs blanket screening for breast, ovarian cancer mutations
Research led by Queen Mary University of London has concluded that whole-population testing for mutations linked with a higher risk of breast and ovarian cancer is cost-effective.
Cabometyx trial halted early on success in liver cancer
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Blood cancer care needs improving, finds MP inquiry
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
Speedy EU, US review for Novartis’ CAR-T therapy Kymriah
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR-T therapy Kymriah.
Pfizer asked to submit CDF proposal for Xalkori
Pfizer’s Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer.
